Shire plc

With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing

An analysis of $1B+ takeouts in 2016-24 finds biotechs opting for the billion dollar exit door in robust numbers

BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris

Plus: Biogen alum Radhakrishnan joins Sofinnova Investments, and updates from Bicycle, iTeos, Fennec, Faron and ORIC

Plus Madrigal’s follow-on is among the year’s largest, and PureTech returns cash to shareholders following Karuna takeout

Boston, Mass.-based neuropsychiatry company is developing non-hallucinogenic compounds that promote neuroplasticity  

University of Nantes spinout heading toward clinic with €27.3M from international syndicate

FDA commissioner endorses Inflation Reduction Act, unlikely to change course on accelerated approval

Swedish company pays 89% premium to add Vonjo to hematology portfolio, a year after its accelerated approval in a disease space dominated by Jakafi

Plus: Goswami becomes CFO at Illumina, and updates from SOBI, BDGene, Nordic and more